Ilene L Hollin1,2, Holly Peay3, Ryan Fischer4, Ellen M Janssen5, John F P Bridges5. 1. University of Southern California Schaeffer Center for Health Economics and Policy, Los Angeles, CA, USA. ihollin@npcnow.org. 2. National Pharmaceutical Council, Washington, DC, USA. ihollin@npcnow.org. 3. RTI International, Center for Newborn Screening, Ethics, and Disability Studies, Research Triangle Park, NC, USA. 4. Parent Project Muscular Dystrophy, Hackensack, NJ, USA. 5. Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Abstract
PURPOSE: Patient preference information (PPI) have an increasing role in regulatory decision-making, especially in benefit-risk assessment. PPI can also facilitate prioritization of symptoms to treat and inform meaningful selection of clinical trial endpoints. We engaged patients and caregivers to prioritize symptoms of Duchenne and Becker muscular dystrophy (DBMD) and explored preference heterogeneity. METHODS: Best-worst scaling (object case) was used to assess priorities across 11 symptoms of DBMD that impact quality of life and for which there is unmet need. Respondents selected the most and least important symptoms to treat among a subset of five. Relative importance scores were estimated for each symptom, and preference heterogeneity was identified using mixed logit and latent class analysis. RESULTS: Respondents included patients (n = 59) and caregivers (n = 96) affected by DBMD. Results indicated that respondents prioritized "weaker heart pumping" [score = 5.13; 95% CI (4.67, 5.59)] and pulmonary symptoms: "lung infections" [3.15; (2.80, 3.50)] and "weaker ability to cough" [2.65; (2.33, 2.97)] as the most important symptoms to treat and "poor attention span" as the least important symptom to treat [- 5.23; (- 5.93, - 4.54)]. Statistically significant preference heterogeneity existed (p value < 0.001). At least two classes existed with different priorities. Priorities of the majority latent class (80%) reflected the aggregate results, whereas the minority latent class (20%) did not distinguish among pulmonary and other symptoms. CONCLUSIONS: Estimates of the relative importance for symptoms of Duchenne muscular dystrophy indicated that symptoms with direct links to morbidity and mortality were prioritized above other non-skeletal muscle symptoms. Findings suggested the existence of preference heterogeneity for symptoms, which may be related to symptom experience.
PURPOSE:Patient preference information (PPI) have an increasing role in regulatory decision-making, especially in benefit-risk assessment. PPI can also facilitate prioritization of symptoms to treat and inform meaningful selection of clinical trial endpoints. We engaged patients and caregivers to prioritize symptoms of Duchenne and Becker muscular dystrophy (DBMD) and explored preference heterogeneity. METHODS: Best-worst scaling (object case) was used to assess priorities across 11 symptoms of DBMD that impact quality of life and for which there is unmet need. Respondents selected the most and least important symptoms to treat among a subset of five. Relative importance scores were estimated for each symptom, and preference heterogeneity was identified using mixed logit and latent class analysis. RESULTS: Respondents included patients (n = 59) and caregivers (n = 96) affected by DBMD. Results indicated that respondents prioritized "weaker heart pumping" [score = 5.13; 95% CI (4.67, 5.59)] and pulmonary symptoms: "lung infections" [3.15; (2.80, 3.50)] and "weaker ability to cough" [2.65; (2.33, 2.97)] as the most important symptoms to treat and "poor attention span" as the least important symptom to treat [- 5.23; (- 5.93, - 4.54)]. Statistically significant preference heterogeneity existed (p value < 0.001). At least two classes existed with different priorities. Priorities of the majority latent class (80%) reflected the aggregate results, whereas the minority latent class (20%) did not distinguish among pulmonary and other symptoms. CONCLUSIONS: Estimates of the relative importance for symptoms of Duchenne muscular dystrophy indicated that symptoms with direct links to morbidity and mortality were prioritized above other non-skeletal muscle symptoms. Findings suggested the existence of preference heterogeneity for symptoms, which may be related to symptom experience.
Authors: Na Guo; Carlo A Marra; J Mark FitzGerald; R Kevin Elwood; Aslam H Anis; Fawziah Marra Journal: Value Health Date: 2011-07-29 Impact factor: 5.725
Authors: Daniel A Waschbusch; Charles E Cunningham; William E Pelham; Heather L Rimas; Andrew R Greiner; Elizabeth M Gnagy; James Waxmonsky; Gregory A Fabiano; Jessica A Robb; Lisa Burrows-Maclean; Mindy Scime; Martin T Hoffman Journal: J Clin Child Adolesc Psychol Date: 2011
Authors: Yu-Ning Wong; Brian L Egleston; Kush Sachdeva; Naa Eghan; Melanie Pirollo; Tammy K Stump; John Robert Beck; Katrina Armstrong; Jerome Sanford Schwartz; Neal J Meropol Journal: Med Care Date: 2013-09 Impact factor: 2.983
Authors: Alison M Barnard; Donovan J Lott; Abhinandan Batra; William T Triplett; Sean C Forbes; Samuel L Riehl; Rebecca J Willcocks; Barbara K Smith; Krista Vandenborne; Glenn A Walter Journal: J Neurol Date: 2019-07-26 Impact factor: 4.849
Authors: Anne L R Schuster; Norah L Crossnohere; Ryan Fischer; Patricia Furlong; John F P Bridges Journal: Ther Innov Regul Sci Date: 2022-03-24 Impact factor: 1.778